Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$218.11
-1.0%
$173.69
$96.09
$234.29
$11.22B0.59700,919 shs122,391 shs
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$224.40
-1.1%
$192.62
$97.56
$230.40
$14.09B0.271.01 million shs121,758 shs
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$50.71
+1.0%
$47.62
$32.15
$51.65
$29.25B0.43.50 million shs436,947 shs
Zoetis Inc. stock logo
ZTS
Zoetis
$82.91
-5.0%
$118.49
$83.55
$172.23
$34.87B0.874.45 million shs4.25 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-1.26%+5.81%+30.27%+20.42%+98.29%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
-0.70%+11.79%+18.86%+37.14%+123.74%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
-1.11%+0.22%+7.10%+12.43%+53.26%
Zoetis Inc. stock logo
ZTS
Zoetis
-22.02%-24.42%-25.57%-31.72%-44.29%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$218.11
-1.0%
$173.69
$96.09
$234.29
$11.22B0.59700,919 shs122,391 shs
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$224.40
-1.1%
$192.62
$97.56
$230.40
$14.09B0.271.01 million shs121,758 shs
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$50.71
+1.0%
$47.62
$32.15
$51.65
$29.25B0.43.50 million shs436,947 shs
Zoetis Inc. stock logo
ZTS
Zoetis
$82.91
-5.0%
$118.49
$83.55
$172.23
$34.87B0.874.45 million shs4.25 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-1.26%+5.81%+30.27%+20.42%+98.29%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
-0.70%+11.79%+18.86%+37.14%+123.74%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
-1.11%+0.22%+7.10%+12.43%+53.26%
Zoetis Inc. stock logo
ZTS
Zoetis
-22.02%-24.42%-25.57%-31.72%-44.29%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.90
Moderate Buy$251.2615.20% Upside
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2.83
Moderate Buy$230.562.74% Upside
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
3.00
Buy$53.715.92% Upside
Zoetis Inc. stock logo
ZTS
Zoetis
2.40
Hold$149.6780.52% Upside

Current Analyst Ratings Breakdown

Latest JAZZ, AXSM, ZTS, and RPRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2026
Zoetis Inc. stock logo
ZTS
Zoetis
Set Price Target$105.00
5/7/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Reiterated RatingOverweight$245.00
5/7/2026
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
Boost Price TargetBuy$50.00 ➝ $66.00
5/7/2026
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
Boost Price TargetOverweight$50.00 ➝ $58.00
5/6/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Reiterated RatingOutperform$239.00
5/6/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Boost Price TargetBuy$220.00 ➝ $275.00
5/6/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Set Price Target$252.00
5/6/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Boost Price TargetOverweight$225.00 ➝ $234.00
5/6/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Boost Price TargetOutperform$195.00 ➝ $258.00
5/6/2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
Boost Price TargetOverweight$250.00 ➝ $265.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Set Price Target$280.00
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$708.24M15.85N/AN/A$1.06 per share205.76
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$4.27B3.30$15.96 per share14.06$72.24 per share3.11
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$2.44B11.99$4.77 per share10.62$16.83 per share3.01
Zoetis Inc. stock logo
ZTS
Zoetis
$9.47B3.68$5.64 per share14.70$7.56 per share10.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.73N/A54.12N/A-26.59%-267.16%-28.53%N/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
-$356.15M-$0.02N/A10.130.400.66%14.56%5.25%N/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$770.95M$1.4734.509.273.2433.88%29.49%14.85%N/A
Zoetis Inc. stock logo
ZTS
Zoetis
$2.67B$6.0213.7710.951.7128.24%62.02%19.24%N/A

Latest JAZZ, AXSM, ZTS, and RPRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Zoetis Inc. stock logo
ZTS
Zoetis
$1.60$1.53-$0.07$1.42$2.30 billion$2.26 billion
5/6/2026Q1 2026
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$1.22$1.30+$0.08$0.67$881.69 million$631.00 million
5/5/2026Q1 2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$4.67$6.34+$1.67$4.43$978.46 million$974.98 million
5/4/2026Q1 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million
3/31/2026Q1 2026
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
N/A$6.34N/A$4.43N/A$1.07 billion
2/25/2026Q4 2025
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
$6.49$6.64+$0.15$3.21$1.17 billion$1.20 billion
2/23/2026Q4 2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.70-$0.56+$0.14-$0.56$191.33 million$196.00 million
2/12/2026Q4 2025
Zoetis Inc. stock logo
ZTS
Zoetis
$1.40$1.48+$0.08$1.37$2.36 billion$2.39 billion
2/11/2026Q4 2025
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$1.33$1.46+$0.13$0.50$839.97 million$621.99 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
N/AN/AN/AN/AN/A
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
$0.941.85%+24.01%63.95%5 Years
Zoetis Inc. stock logo
ZTS
Zoetis
$2.122.56%+20.11%35.22%14 Years

Latest JAZZ, AXSM, ZTS, and RPRX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/17/2026
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
quarterly$0.23501.88%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.27
1.39
1.48
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
0.95
2.04
1.67
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
0.88
2.40
2.40
Zoetis Inc. stock logo
ZTS
Zoetis
2.71
3.03
1.94

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
89.14%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
54.35%
Zoetis Inc. stock logo
ZTS
Zoetis
92.80%

Insider Ownership

CompanyInsider Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
4.30%
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
18.84%
Zoetis Inc. stock logo
ZTS
Zoetis
0.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38051.46 million40.86 millionOptionable
Jazz Pharmaceuticals PLC stock logo
JAZZ
Jazz Pharmaceuticals
2,89062.74 million60.04 millionOptionable
Royalty Pharma PLC stock logo
RPRX
Royalty Pharma
80576.86 million468.18 millionOptionable
Zoetis Inc. stock logo
ZTS
Zoetis
14,500420.64 million419.72 millionOptionable

Recent News About These Companies

Zoetis Earnings Call Balances Strength And Strain
Promising Medical Stocks To Research - May 7th
Why Zoetis Shares Plummeted Today
Zoetis Inc. (ZTS) Q1 2026 Earnings Call Transcript
US Pet Care Demand Is Weak - Zoetis Cuts Outlook
US Pet Care Demand Is Weak - Zoetis Cuts Outlook
Zoetis Is Today's Worst S&P 500 Stock. Here's Why.
Zoetis (NYSE:ZTS) Shares Gap Down After Earnings Miss
Zoetis Inc. 2026 Q1 - Results - Earnings Call Presentation
Zoetis (NYSE:ZTS) Updates FY 2026 Earnings Guidance
Bokf Na Reduces Position in Zoetis Inc. $ZTS

New MarketBeat Followers Over Time

Media Sentiment Over Time

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$218.11 -2.11 (-0.96%)
As of 11:07 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Jazz Pharmaceuticals stock logo

Jazz Pharmaceuticals NASDAQ:JAZZ

$224.40 -2.56 (-1.13%)
As of 11:07 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Royalty Pharma stock logo

Royalty Pharma NASDAQ:RPRX

$50.71 +0.51 (+1.02%)
As of 11:07 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Zoetis stock logo

Zoetis NYSE:ZTS

$82.91 -4.40 (-5.04%)
As of 11:07 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.